Mr. Borna Zlamalik reports

ORGANIGRAM EXTENDS INNOVATION INVESTMENT WITH PHYLOS

Organigram Global Inc. has expanded its innovation investment in Phylos Bioscience Inc., securing Organigram's position as a leader in seed-based cannabis genetics. Through an amended loan and product agreement, Organigram gains priority access to Phylos's autoflower genetics pipeline, including preferential economic terms and long-term rights in its international markets, establishing a foundation for product differentiation and growth in recreational and medical markets.

Operational security through a long-term seed pipeline

According to Borna Zlamalik, senior vice-president, innovation and international R&D (research and development), at Organigram: "Seed-based cultivation has become a key advantage of Organigram's cultivation strategy, giving us unprecedented consistency, scalability and economic benefit. Our follow-on investment in Phylos secures the portfolio breadth of next-generation cultivars required to meet the needs of Organigram's consumers and patients."

International exclusivity for genetics

Under the amended product agreement, Organigram receives five-year exclusivity on its chosen autoflower cultivars across international markets, including Canada, Australia, the United Kingdom, Germany and Israel, with the ability to add new exclusive territories as it expands globally. Annual portfolio reviews will maintain exclusivity only for commercially relevant cultivars, maximizing flexibility and strengthening Organigram's international product differentiation strategy as it enters high-value medical markets.

Convertible loan top-up

Under the terms of the amended loan agreement, Organigram will consolidate its existing investment with a new $3-million (U.S.) advance, resulting in a combined total loan principal of $10-million (U.S.). The loan matures on May 25, 2028, and is subject to conversion or other resolution mechanisms under the amended agreement.

Investing in the future of seed-based cannabis

Ralph Risch, chief executive officer of Phylos, noted: "Organigram saw early that the next phase of cannabis production would be driven by scientifically bred genetics. Their investment allows Phylos to accelerate development of new traits and F1 hybrid seeds while giving Organigram a meaningful economic advantage as the first to deploy those innovations at commercial scale."

About Organigram Global Inc.

Organigram Global is a company (listed on the Nasdaq Global Select Market and the Toronto Stock Exchange) whose wholly owned subsidiary, Organigram Inc., is a licensed cultivator of cannabis and manufacturer of cannabis-derived goods in Canada. Through its acquisition of Collective Project Ltd., Organigram Global participates in the U.S. and Canadian cannabinoid beverage markets.

Organigram is focused on producing high-quality cannabis for adult consumers as well as developing international business partnerships to extend the company's global footprint. Organigram has also developed and acquired a portfolio of cannabis brands, including Edison, Big Bag O' Buds, Shred, Monjour, Tremblant, Collective Project, Trailblazer, Boxhot and Debunk. Organigram operates facilities in Moncton, N.B., and Lac-Superieur, Que., with a dedicated edibles manufacturing facility in Winnipeg, Man. The company also operates two additional cannabis processing facilities in Southwestern Ontario -- one in Aylmer and the other in London. The facility in Aylmer houses best-in-class extraction capabilities and is optimized for formulation refinement, postprocessing of minor cannabinoids and infused preroll production. The facility in London will be optimized for labelling, packaging and national fulfilment. The company is regulated by Health Canada under the Cannabis Act and the Cannabis Regulations.

We seek Safe Harbor.